DOES LOW-DOSE ACETYLSALICYLIC-ACID PREVENT STROKE AFTER CAROTID SURGERY - A DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL

被引:133
作者
LINDBLAD, B
PERSSON, NH
TAKOLANDER, R
BERGQVIST, D
机构
[1] Department of Surgery, Malmö General Hospital, Lund University, Malmö
关键词
ASPIRIN; CAROTID ENDARTERECTOMY; CLINICAL TRIALS;
D O I
10.1161/01.STR.24.8.1125
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose: The aim of this randomized double-blind, placebo-controlled trial was to evaluate whether neurological deficits could be prevented with low-dose acetylsalicylic acid (ASA) as an adjunct to carotid endarterectomy. Methods: A total of 232 patients were randomized to two groups, 75 mg/d ASA starting preoperatively and continued for 6 months (n = 117) or placebo (identical tablets) (n = 115). The patients were followed up regularly for 1 year. Results: The groups were well matched regarding laboratory data and indication for operation. The number of patients with intraoperative or postoperative stroke without complete recovery within 1 week were 0 and 2 at 30 days and 6 months, respectively, in the ASA group, compared with 7 and 11 in the placebo group (P=.01). Including all neurological events within 6 months, this was found in 15 patients in the ASA group compared with 24 in the placebo group (P=.12). Mortality was 0.8% and 3.4% at 30 days and 6 months, respectively, in the ASA group. In the placebo group, the corresponding figures were 4.3% and 6.0%, respectively (P=.12). The intraoperative bleeding did not differ between the groups nor did the number of reoperations due to bleeding or other complications related to pharmacology. Conclusions: This study indicates that low-dose ASA (75 mg/d) reduces the number of postoperative strokes without complete recovery within 1 week. Overall neurological events are insignificantly reduced, as also mortality. The use of low-dose ASA (75 mg) seems safe and effective in reducing cerebrovascular events after carotid endarterectomy.
引用
收藏
页码:1125 / 1128
页数:4
相关论文
共 16 条
[1]  
[Anonymous], 1988, LANCET, V2, P349
[2]  
[Anonymous], 1988, BRIT MED J, V296, P320
[3]  
[Anonymous], 1991, Lancet, V338, P1345
[4]   AICLA CONTROLLED TRIAL OF ASPIRIN AND DIPYRIDAMOLE IN THE SECONDARY PREVENTION OF ATHERO-THROMBOTIC CEREBRAL-ISCHEMIA [J].
BOUSSER, MG ;
ESCHWEGE, E ;
HAGUENAU, M ;
LEFAUCCONNIER, JM ;
THIBULT, N ;
TOUBOUL, D ;
TOUBOUL, PJ .
STROKE, 1983, 14 (01) :5-14
[5]   DANISH VERY-LOW-DOSE ASPIRIN AFTER CAROTID ENDARTERECTOMY TRIAL [J].
BOYSEN, G ;
SORENSEN, PS ;
JUHLER, M ;
ANDERSEN, AR ;
BOAS, J ;
OLSEN, JS ;
JOENSEN, P .
STROKE, 1988, 19 (10) :1211-1215
[6]   CONTROLLED TRIAL OF ASPIRIN IN CEREBRAL ISCHEMIA [J].
FIELDS, WS ;
LEMAK, NA ;
FRANKOWSKI, RF ;
HARDY, RJ .
STROKE, 1977, 8 (03) :301-316
[7]   CONTROLLED TRIAL OF ASPIRIN IN CEREBRAL ISCHEMIA .2. SURGICAL GROUP [J].
FIELDS, WS ;
LEMAK, NA ;
FRANKOWSKI, RF ;
HARDY, RJ .
STROKE, 1978, 9 (04) :309-319
[8]  
Forssell C, 1988, Eur J Vasc Surg, V2, P93, DOI 10.1016/S0950-821X(88)80055-0
[9]  
Forssell C, 1988, Eur J Vasc Surg, V2, P9, DOI 10.1016/S0950-821X(88)80100-2
[10]   PROSTAGLANDINS, PLATELETS, AND ATHEROSCLEROSIS [J].
GRYGLEWSKI, RJ .
CRC CRITICAL REVIEWS IN BIOCHEMISTRY, 1980, 7 (04) :291-338